Table 1.
Afatinib‐resistant cell lines and the resistance mechanisms
| Cell lines | Afatinib exposure | HER2 amp/mut | MET amp | EMT | CSC markers |
|---|---|---|---|---|---|
| Calu3 | N/A | amp | − | − | − |
| Calu3‐ARS | Stepwise | amp | + | − | − |
| Calu3‐ARH | High | amp | − | + | − |
| H2170 | N/A | amp | − | − | − |
| H2170‐ARS | Stepwise | Loss of amp | − | − | − |
| H2170‐ARH | High | Loss of amp | − | − | − |
| H1781 | N/A | mut (G776VC) | − | − | − |
| H1781‐ARS | Stepwise | mut (G776VC) | − | − | + |
| H1781‐ARH | High | mut (G776VC) | − | − | + |
amp, amplification; CSC, cancer stem cell; EMT, epithelial‐to‐mesenchymal transition; mut, mutation; N/A, not applicable.